India, Nov. 9 -- Morepen Laboratories Limited has announced its entry into the US prescription generics market with the launch of its first prescription generic product, Desloratadine Tablets USP, 5 mg, in 100-count and 500-count packs.
The product will be distributed in the US market through the company's wholly owned US subsidiary, Morepen Bio Inc.
The launch builds on Morepen's established presence in the US market as a supplier of Desloratadine active pharmaceutical ingredients (API) for several years. With this move, the company is expanding its presence across the pharmaceutical value chain, moving from API supplies into finished-dosage formulations and distribution in the US.
Sanjay Suri, Managing Director of Morepen Laboratories,...